ARTV News & Events

Artiva Biotherapeutics announced the appointment of Thad Huston as Chief Financial Officer. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation.

Artiva Biotherapeutics announced the appointment of Elaine Sorg to its Board of Directors. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as Humira and Rinvoq for rheumatoid arthritis.

Artiva Biotherapeutics announced positive initial safety and translational data from ongoing clinical trials of AlloNK in combination with rituximab or obinutuzumab for the treatment of autoimmune disease. The findings highlight that AlloNK, an allogeneic, non-genetically modified, cryopreserved, off-the-shelf natural killer cell therapy, was generally well tolerated and demonstrated deep B-cell depletion in outpatient and community settings. Artiva remains on track to share initial clinical response data and conduct U.S. Food and Drug Administration regulatory interactions to align on pivotal trial design for AlloNK in refractory rheumatoid arthritis in the first half of 2026

"During the third quarter, we continued to execute on our mission to deliver accessible, scalable immunotherapies for autoimmune disease. We have now treated over a hundred patients with AlloNK across oncology and autoimmune disease, a significant milestone for the company," said Fred Aslan, M.D., President and Chief Executive Officer of Artiva. "With refractory rheumatoid arthritis now established as our lead indication and Fast Track designation granted by the FDA, we have taken an important step forward in the development of AlloNK. We look forward to sharing the emerging translational and safety data later today, supporting AlloNK's profile as an outpatient-ready therapy capable of achieving deep B-cell depletion, followed by clinical response data in the first half of 2026 from more than 15 refractory RA patients, several of whom will have six or more months of follow-up. In addition, we are planning FDA interactions in the first half of 2026 that could enable AlloNK to become the first deep B-cell depleting therapy to advance to a pivotal trial in patients with RA."